

Title (en)  
DEATH DOMAIN CONTAINING RECEPTOR 4

Title (de)  
"DEATH-DOMAIN"ENTHALTENDER REZEPTOR

Title (fr)  
RECEPTEUR 4 CONTENANT LE DOMAINE DE LA MORT CELLULAIRE PROGRAMMEE

Publication  
**EP 1178828 A4 20041013 (EN)**

Application  
**EP 00932061 A 20000505**

Priority  
• US 0012163 W 20000505  
• US 13292299 P 19990506

Abstract (en)  
[origin: WO0067793A1] The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.

IPC 1-7  
**A61K 39/395**

IPC 8 full level  
**G01N 33/574** (2006.01); **A61K 38/00** (2006.01); **A61K 38/21** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 47/48** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/02** (2006.01); **C07K 14/705** (2006.01); **C07K 14/715** (2006.01); **C07K 16/28** (2006.01); **C07K 19/00** (2006.01); **C12N 15/02** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01)

CPC (source: EP)  
**A61K 39/39541** (2013.01); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/02** (2017.12); **C07K 14/70578** (2013.01); **C07K 14/7151** (2013.01); **C07K 16/2878** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/30** (2013.01); **C12N 2799/026** (2013.01)

Citation (search report)  
• [Y] WO 9832856 A1 19980730 - HUMAN GENOME SCIENCES INC [US], et al  
• [Y] WO 9902653 A1 19990121 - UNIV PENNSYLVANIA [US], et al  
• [PX] WO 9937684 A1 19990729 - GENENTECH INC [US]  
• [Y] KIM K H ET AL: "Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal and cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 486, XP008033656, ISSN: 0197-016X  
• [Y] DELGADO C ET AL: "RESEARCH ARTICLE. QUANTITATIVE ANALYSIS OF POLYETHYLENE GLYCOL (PEG) IN PEG-MODIFIED PROTEINS/ CYTOKINES BY AQUEOUS TWO-PHASE SYSTEMS", JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, AMSTERDAM, NL, vol. 29, 1994, pages 237 - 250, XP000974417, ISSN: 0165-022X  
• [T] CHANTRY D: "Tumour necrosis factor antagonists", EMERGING DRUGS 1999 UNITED KINGDOM, vol. 4, 1999, pages 5 - 13, XP008033630, ISSN: 1361-9195  
• [T] MARSTERS S A ET AL: "Control of apoptosis signaling by Apo2 ligand.", RECENT PROGRESS IN HORMONE RESEARCH. 1999, vol. 54, 1999, pages 225 - 234, XP008033658, ISSN: 0079-9963  
• See references of WO 0067793A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0067793 A1 20001116; WO 0067793 A8 20010525; WO 0067793 A9 20020418**; AU 4984300 A 20001121; CA 2373063 A1 20001116; EP 1178828 A1 20020213; EP 1178828 A4 20041013; JP 2002544172 A 20021224

DOCDB simple family (application)  
**US 0012163 W 20000505**; AU 4984300 A 20000505; CA 2373063 A 20000505; EP 00932061 A 20000505; JP 2000616818 A 20000505